Resource
The VRd regimen combines three drug classes used to treat myeloma: the proteasome inhibitor Velcade®, the immunomodulatory agent Revlimid®, and the steroid dexamethasone. Each drug has a different way of attacking myeloma, and each enhances the activity of the other drugs in this combination. VRd…
Resource
The immune system involves multiple mechanisms that work together to protect and defend the human body from external threats such as bacteria, viruses, and toxins, and from internal threats such as cancer. Myeloma is a cancer of the immune system and it is important for patients with myeloma to…
Resource
Sarclisa Escena is a newer formulation of Sarclisa. Both are approved by the FDA for treating patients with newly diagnosed multiple myeloma (NDMM) or with relapsed/refractory multiple myeloma (RRMM). Both formulations have the same active ingredient and are very effective in treating myeloma.*…
Blog post
Living With Myeloma: Joyce’s Story of Hope, Access, and Advocacy The International Myeloma Foundation continues to share this collection of patient and care partner stories from those who have completed the Legislative Advocacy Master Class (LAMC). The IMF hopes that these unique and…
Resource
Monoclonal gammopathy of undetermined significance (MGUS) is a non-cancerous condition associated with the possible subsequent development of myeloma. Smoldering multiple myeloma (SMM) is an asymptomatic precursor to active disease; the FDA granted its first-ever approval of a treatment for SMM in…
Resource
Isa-VRd is an effective “quadruplet” (4-drug) regimen that combines medicines from 4 drug classes: the monoclonal antibody Sarclisa® (isatuximab-irfc) + the proteasome inhibitor Velcade® (bortezomib) + the immunomodulatory agent Revlimid® (lenalidomide) + the steroid dexamethasone. In September…
Resource
Revlimid® (lenalidomide) is an oral medication in a class of drugs called immunomodulatory agents. It was first approved by the U.S. Food and Drug Administration (FDA) for patients with myeloma in 2006. Since then, the FDA has approved numerous combination therapies with Revlimid for treatment…
Resource
Updated in September 2026, the IMF Patient Handbook offers an overview of myeloma, including its precursor conditions, diagnosis, risk stratification, and effects on the body. We hope that you will find this booklet useful. Information about treatments currently approved…
Resource
Talvey® (talquetamab-tgvs) is indicated for adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy. Talvey is the first bispecific antibody approved by the FDA that has one of its two “arms” attaching to the myeloma cell through the…
Resource
Empliciti® (elotuzumab) is the first immunostimulatory monoclonal antibody approved for the treatment of myeloma. Empliciti enlists immune system cells to attack myeloma. Before reading this booklet, it may be helpful to read another IMF publication,…
Resource
The IMF’s Understanding Stem Cell Transplant in Myeloma publication is intended for myeloma patients in the United States who are in discussions with their treating doctors about the possibility of having an autologous stem cell transplant (ASCT) as part of their overall treatment strategy…
News Article
European Commission Approves Expanded Indication for Teclistamab Monotherapy as Treatment for Relapsed/Refractory MyelomaEC approval was based on phase 3 MajesTEC-9 results, which showed a 71% reduction in the risk of disease progression or death, and a 40% reduction in the risk of death compared…
Resource
Care partners walk alongside their loved ones to help them live well with myeloma. Care partners are individuals who provide essential physical, emotional, and practical support to patients with myeloma.
We Thank Our Sponsors: Janssen Oncology and Pfizer
Resource
This booklet discusses Darzalex® and Darzalex Faspro®, two formulations of an equally effective medication. This targeted therapy enlists the human immune system to help attack and kill myeloma cells, making it easier for healthy cells to recover after treatment. Darzalex is an FDA-approved…
Blog post
Frequently asked questions on the FDA-accelerated approval of Zenbexus (iberdomide), in combination with multiple myeloma indications On Thursday, August 13, the U.S. Food and Drug Administration (FDA) granted accelerated approval to ZENBEXUS™ (iberdomide), in combination with Darzalex…
Resource
In the Summer 2026 edition of Myeloma Today, explore key research presented at the American Society of Clinical Oncology (ASCO) and European Hematology Association (EHA) annual meetings, including advances in frontline, maintenance, and relapsed myeloma treatments. Get an inside look at the IMF…
Resource
Protecting yourself and your medical information
Videos
Could Two Years of Myeloma Maintenance Be Enough? What the ENDURANCE Clinical Trial Found Do you need multiple myeloma maintenance therapy forever? Dr. Joseph Mikhael of the International Myeloma Foundation explains the ENDURANCE clinical trial and what its findings may mean for patients…
Resource
The steroid dexamethasone (“dex”) is helpful in the treatment of conditions that affect the immune system, such as myeloma. Dex as part of combination therapies improves the ability of other drugs to destroy myeloma cells. Dex has many benefits. It also comes with dose-related side effects:…
Resource
Gain a basic understanding of myeloma —what the disease is, its incidence, its symptoms, and how to get support.
News Article
The International Myeloma Foundation Launches US Myeloma Network to Accelerate Clinical Trials, Expand Access, and Improve Patient Care STUDIO CITY, CA, October 22, 2026 — Today, the International Myeloma Foundation (IMF) announced the launch of the US Myeloma Network (USMN…
Resource
Clinical trials are research studies that involve patients (after laboratory studies have demonstrated that a new drug, treatment, or procedure works better than existing methods). The goal of a myeloma clinical trial is to improve patient care. Whether or not to participate in a clinical trial is…
Resource
Pomalyst® (pomalidomide) is a medication used to treat adult patients with relapsed or refractory multiple myeloma (RRMM) who have received at least 2 prior therapies and whose myeloma got worse on or within 60 days of finishing their last therapy. This booklet explains how Pomalyst works, the…
Resource
In July 2025, the FDA approved the use of Lynozyfic™ (linvoseltamab-gcpt) for the treatment of adult patients with relapsed/refractory multiple myeloma (RRMM) who have received at least 4 prior lines of therapy. This booklet explains how Lynozyfic works, its dose and schedule, clinical trial…
Resource
The success of an oral treatment depends on your ability to follow the plan agreed upon by you and your doctor. To achieve the best results when you take medication by mouth, you take on the responsibility of adhering to your treatment as prescribed.
Resource
Myeloma is a complicated disease, but the language that describes it doesn’t have to be hard to understand. To play an active role in your own medical care, it is helpful to learn the myeloma-related terms that may be used in your discussions with your doctor, who is best able to answer questions…
Resource
There are two Ninlaro-based treatment options to be considered by patients who can benefit from an all-oral drug regimen. Ninlaro® (ixazomib) + Revlimid® (lenalidomide) + dexamethasone is a triplet (3-drug) combination known as IRd, approved by the FDA for the treatment of patients with myeloma who…
Resource
A support network is a group of people who can assist during times of need. A support network is helpful whether or not you have a single go-to care partner. Developing a support network lessens the burden on any one individual. People with a more robust support network tend to have better health…
Resource
Immunotherapy with Abecma® (idecabtagene vicleucel or “ide-cel” for short) is FDA-approved for the treatment of relapsed refractory multiple myeloma (RRMM) after 2 or more prior lines of therapy. Immunotherapy is treatment that enhances the body’s natural defenses. Chimeric antigen receptor (CAR) T…
Resource
From newly approved 4-drug frontline regimens to the expanding role of CAR T-cell therapy and bispecific antibodies, this Spring 2026 edition of Myeloma Today breaks down the clinical advances redefining what’s possible for myeloma patients today. You’ll also discover how a global movement reached…
Resource
Chimeric antigen receptor (CAR) T-Cell therapy is a cutting-edge, personalized treatment for myeloma that uses your own T-cells to target cancer. The process involves collecting and modifying your T-cells, followed by infusion and close monitoring. CAR-T is highly effective, especially for…
Resource
Based on data emerging from currently ongoing clinical trials, FDA approvals of other quadruplet regimens are anticipated in the near future.
Resource
This booklet explains the tests used to diagnose, monitor, and assess myeloma. Tests determine if and when treatment is needed. Tests identify genetic risk factors, response to treatment, risk of disease progression, and potential myeloma-related and treatment-related side effects. Each test is a…
Resource
This booklet discusses Blenrep® (belantamab mafodotin-blmf), an antibody-drug conjugate (ADC) that is a combination of a monoclonal antibody and a chemotherapy agent. Blenrep is the first and only medication in the ADC drug class that has been approved by the FDA to treat myeloma. Blenrep is unique…
Resource
This booklet will familiarize you with myeloma-related bone disease (MBD) and the therapies available to prevent or treat it. Approximately 70%–80% of people with myeloma develop MBD, which can cause bones to become thinner and weaker, and can create holes in bone. The weakened bone is more likely…
News Article
CHMP recommendation would offer a GPRC5D-targeting bispecific antibody treatment option as early as the second line of therapy, if approved by the European Commission. On Friday, October 16, the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) recommended…
Videos
Myeloma and its treatments can affect desire, arousal, intimacy, body image, and fertility, yet these topics are rarely discussed. In this Living Well with Myeloma webinar, IMF Associate Director of Support Groups Katie Atkins, MSW, LCSW, speaks with Monika Brown, women's health nurse practitioner…
Resource
The 2026 Winter Edition of Myeloma Today highlights IMF Chief Medical Officer Dr. Joseph Mikhael’s top 10 myeloma research abstracts from the American Society of Hematology (ASH) Annual Meeting & Exposition, including a discussion on in vivo CAR T-cell therapy and key results from the…
Resource
Xpovio® (selinexor) is a selective inhibitor of nuclear export (SINE) compound. In 2019, Xpovio became the first medication in this drug class to receive approval from the U.S. Food and Drug Administration (FDA). Xpovio was initially used for the treatment of relapsed/refractory multiple myeloma (…
Resource
Tecvayli® (also known as teclistamab-cqyv, its generic drug name) is an immunotherapy that enhances a patient’s own immune system to attack myeloma cells. This booklet explains who can be treated with Tecvayli, how it works, how it is given, and how side effects that may occur in patients treated…
Resource
Immunotherapy is treatment that engages the patient’s own immune system to attack their myeloma. Currently, there are three types of immunotherapies approved by the U.S. Food and Drug Administration (FDA) for the treatment of myeloma: monoclonal antibodies, bispecific antibodies, and chimeric…
Resource
The Fall 2025 edition of Myeloma Today celebrates the International Myeloma Foundation's remarkable 35-year journey of defying boundaries and redefining possibilities in the fight against myeloma. This milestone issue welcomes new President & CEO Heather Cooper Ortner, highlights groundbreaking…
Resource
This booklet serves as an introduction to cereblon E3 ligase modulatory drugs (CELMoDs), a new class of medications currently being studied in clinical trials for the treatment of myeloma. Although CELMoDs are building on the well-established platform of immunomodulatory agents, CELMoDs are…
Resource
Multiple myeloma is a chronic condition that impacts the person with the diagnosis and their loved ones, especially those involved in caregiving. Care partners provide support in many ways, finding the role both gratifying and stressful. While focusing on their loved ones’ needs, care partners can…
Resource
As treatment for myeloma improves and patients live longer, it is important to reduce the disability that can result from the painful problem of vertebral compression fractures, which occur when the vertebra collapses or fractures because the bone is too weak to withstand the pressure or stress…
Blog post
Top highlights from Day Two of the 12th Annual Global Myeloma Action (GMAN) Summit held in Stockholm, Sweden. The International Myeloma Foundation’s (IMF) 2026 Global Myeloma Action Network Summit took place from June 5-7, 2026, in Stockholm, Sweden — bringing together myeloma patient…
Resource
Carvykti® (ciltacabtagene autoleucel, or “cilta-cel” for short) is a customized immunotherapy approved by the FDA for the treatment of patients with relapsed or refractory multiple myeloma (RRMM) after at least 1 prior line of therapy. Carvykti is the first BCMA-targeted therapy approved for…